KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

Urothelial Carcinoma Clinical Trial

Official title:

An Open-label, Phase 1 Study of KHK2455 in Combination With Avelumab in Adult Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03915405
• Other study ID #: 2455-002
• Secondary ID: 2018-003796-35
• Status: Terminated
• Phase: Phase 1
• Start date: September 26, 2019
• Est. completion date: November 15, 2022

Study information

• Verified date: April 2024
• Source: Kyowa Kirin Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a two-part (dose-escalation, dose-expansion), multicenter, open-label Phase 1 study of KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma (including bladder, urethra, ureters, and renal pelvis).

Description:

This is a two-part (dose-escalation, dose-expansion), multicenter, open-label Phase 1 study of KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma (including bladder, urethra, ureters, and renal pelvis). Subjects will be screened for entry into this study after signing informed consent. Subjects must meet inclusion/exclusion criteria to participate in this study.

• Part 1 (dose-escalation phase) has a modified 3+3 design that will evaluate the safety and tolerability and identify the MTD or highest protocol-defined dose, in the absence of exceeding the MTD.

• Part 2 (cohort-expansion phase) will further explore the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity for the combination regimen at the MTD or highest dose level tested.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 16
• Est. completion date: November 15, 2022
• Est. primary completion date: November 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects may be male or female and must be = 18 years of age; have an ECOG PS of 0 or 1; and a life expectancy of > 3 months in the Investigator's judgment;

• Subjects are able to understand and willing to sign the ICF, according to institutional standards, prior to the initiation of any study related procedures

• Subjects must have histological or cytological evidence of metastatic or advanced urothelial carcinoma (including bladder, urethra, ureters, and renal pelvis that has predominantly transitional cell or urothelial features); and have measurable neoplastic disease according to RECIST v1.1 criteria

• Subjects must have been previously treated with a platinum-based therapy and progressed; OR Been previously treated with platinum based adjuvant or neo-adjuvant therapy and relapsed or progressed; OR

• Be platinum-based chemotherapy intolerant or ineligible; OR

• Have progressed during or after treatment with approved PD-1/PD-L1 inhibitors

• Subjects must have a tumor accessible for fresh biopsy at the baseline visit and for IDO assessment. If current circumstances prohibit the biopsy procedure (e.g., temporary hospital protocol restrictions, regulatory or local authority requirements, etc.) then archived tissue from previous biopsies (fresh frozen tissue < 9 months and formalin fixed-paraffin embedded [FFPE] block of = 24 months) without intervening checkpoint inhibitors can substitute for a fresh baseline biopsy;

• Subjects must be able to swallow the solid (encapsulated) dosage form of KHK2455

Exclusion Criteria:

• Subjects who have been previously treated with avelumab or any IDO1 inhibitor or CTLA-4, PD-1/PD-L1 checkpoint inhibitors; or any investigational immunotherapy including but not limited to anti-cancer vaccines or oncotropic viruses

• Subjects with prior or current liver metastases;

• Subjects with a history of organ transplant or allogeneic bone marrow transplant;

• Subjects with pre-existing uveitis or other known clinically meaningful retinal disorders as determined by a local ophthalmologist

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Transitional Cell
• Urothelial Carcinoma

Intervention

Drug:
• KHK2455
orally, once daily.
• Avelumab
IV Administration

Locations

Country	Name	City	State
Spain	Kyowa Research Site ESP002	Barcelona
Spain	Kyowa Research Site ESP003	Barcelona
Spain	Kyowa Research Site ESP001	Madrid
Spain	Kyowa Research Site ESP004	Madrid
United States	Kyowa Research Site USA 009	Houston	Texas
United States	Kyowa Research Site USA005	Iowa City	Iowa
United States	Kyowa Research Site USA007	Milwaukee	Wisconsin
United States	Kyowa Research Site USA001	Saint Petersburg	Florida
United States	Kyowa Research Site USA006	Santa Fe	New Mexico

Sponsors (1)

Lead Sponsor	Collaborator
Kyowa Kirin, Inc.

Countries where clinical trial is conducted

United States,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-related adverse events as assessed by CTCAE v.5.0	To characterize the safety and tolerability of KHK2455 administered in combination with avelumab in subjects with locally advanced or metastatic urothelial carcinoma (including bladder, urethra, ureters, and renal pelvis).	up to 24 months